BioSpace News Archive

NEOGEN Corporation (NASDAQ: NEOG) announced today that it has acquired Atlanta -based CAPInnoVet, Inc., a companion animal health company that provides pet medications to the veterinary market.

For more information regarding the conferences, or to schedule a one-on-one meeting with Awakn’s management team, please contact your conference representative or KCSA Strategic Communications at Awakn@KCSA.com directly.

Jasper Therapeutics, Inc. and Amplitude Healthcare Acquisition Corporation announced that Lawrence Klein, Ph.D., and Chris Nolet will be appointed to Jasper Therapeutics’ board of directors, effective upon closing of the pending merger between the parties.

Gemina Laboratories Ltd. is pleased to provide an update on its current activities related to the development of its first rapid diagnostic test targeting the SARS CoV-2 antigen, using the Company’s patented breakthrough chemistry.

Galapagos issued 7,600 new ordinary shares on 20 September 2021, for a total capital increase of €151,787.50.

Lucira Health, Inc., a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, announced operations expert Tony Allen has joined the company as Chief Operations Officer.

Solid Biosciences Inc. announced that Joel Schneider, Ph.D., Chief Operating Officer, and Carl Morris, Ph.D., Chief Scientific Officer, will participate at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event and Chardan’s 5th Annual Genetic Medicines Conference.

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the presentation of long-term data from Patients 4-6 in the ongoing IGNITE DMD Phase I/II clinical trial of SGT-001 in patients with Duchenne.

Verrica Pharmaceuticals Inc. (the “Company”) (Nasdaq: VRCA), today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum)

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Virtual Global Healthcare Conference